Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Asia–Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update
Masao Omata, Ann‐Lii Cheng, Norihiro Kokudo, et al.
Hepatology International (2017) Vol. 11, Iss. 4, pp. 317-370
Open Access | Times Cited: 1886

Showing 1-25 of 1886 citing articles:

Hepatocellular Carcinoma
Augusto Villanueva
New England Journal of Medicine (2019) Vol. 380, Iss. 15, pp. 1450-1462
Closed Access | Times Cited: 3625
Global epidemiology of NAFLD-related HCC: trends, predictions, risk factors and prevention
Daniel Q. Huang, Hashem B. El‐Serag, Rohit Loomba
Nature Reviews Gastroenterology & Hepatology (2020) Vol. 18, Iss. 4, pp. 223-238
Open Access | Times Cited: 1328
Hepatocellular carcinoma
Arndt Vogel, Tim Meyer, Gonzalo Sapisochín, et al.
The Lancet (2022) Vol. 400, Iss. 10360, pp. 1345-1362
Closed Access | Times Cited: 1316
Advances in immunotherapy for hepatocellular carcinoma
Bruno Sangro, Pablo Sarobe, Sandra Hervás‐Stubbs, et al.
Nature Reviews Gastroenterology & Hepatology (2021) Vol. 18, Iss. 8, pp. 525-543
Open Access | Times Cited: 931
Epidemiology and surveillance for hepatocellular carcinoma: New trends
Amit G. Singal, Pietro Lampertico, Pierre Nahon
Journal of Hepatology (2020) Vol. 72, Iss. 2, pp. 250-261
Open Access | Times Cited: 877
Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trial
Thomas Yau, Joong‐Won Park, Richard S. Finn, et al.
The Lancet Oncology (2021) Vol. 23, Iss. 1, pp. 77-90
Closed Access | Times Cited: 835
Locoregional therapies in the era of molecular and immune treatments for hepatocellular carcinoma
Josep M. Llovet, Thierry de Baère, Laura Kulik, et al.
Nature Reviews Gastroenterology & Hepatology (2021) Vol. 18, Iss. 5, pp. 293-313
Closed Access | Times Cited: 688
Guidelines for the Diagnosis and Treatment of Hepatocellular Carcinoma (2019 Edition)
Jian Zhou, Hui‐Chuan Sun, Zheng Wang, et al.
Liver Cancer (2020) Vol. 9, Iss. 6, pp. 682-720
Open Access | Times Cited: 648
The Asian Pacific Association for the Study of the Liver clinical practice guidelines for the diagnosis and management of metabolic associated fatty liver disease
Mohammed Eslam, Shiv Kumar Sarin, Vincent Wai‐Sun Wong, et al.
Hepatology International (2020) Vol. 14, Iss. 6, pp. 889-919
Open Access | Times Cited: 646
Randomised, multicentre prospective trial of transarterial chemoembolisation (TACE) plus sorafenib as compared with TACE alone in patients with hepatocellular carcinoma: TACTICS trial
Masatoshi Kudo, Kazuomi Ueshima, Masafumi Ikeda, et al.
Gut (2019) Vol. 69, Iss. 8, pp. 1492-1501
Open Access | Times Cited: 567
Radiomic analysis of contrast-enhanced CT predicts microvascular invasion and outcome in hepatocellular carcinoma
Xun Xu, Hailong Zhang, Qiuping Liu, et al.
Journal of Hepatology (2019) Vol. 70, Iss. 6, pp. 1133-1144
Closed Access | Times Cited: 566
Chronic Hepatitis B Infection
Lydia Tang, Emily Covert, Eleanor Wilson, et al.
JAMA (2018) Vol. 319, Iss. 17, pp. 1802-1802
Closed Access | Times Cited: 564
Management of Hepatocellular Carcinoma in Japan: JSH Consensus Statements and Recommendations 2021 Update
Masatoshi Kudo, Yusuke Kawamura, Kiyoshi Hasegawa, et al.
Liver Cancer (2021) Vol. 10, Iss. 3, pp. 181-223
Open Access | Times Cited: 484
mRECIST for HCC: Performance and novel refinements
Josep M. Llovet, Riccardo Lencioni
Journal of Hepatology (2020) Vol. 72, Iss. 2, pp. 288-306
Open Access | Times Cited: 469
Biology and significance of alpha‐fetoprotein in hepatocellular carcinoma
Peter R. Galle, Friedrich Foerster, Masatoshi Kudo, et al.
Liver International (2019) Vol. 39, Iss. 12, pp. 2214-2229
Open Access | Times Cited: 462
Goals and targets for personalized therapy for HCC
Thomas Couri, Anjana Pillai
Hepatology International (2019) Vol. 13, Iss. 2, pp. 125-137
Closed Access | Times Cited: 452
Challenges of combination therapy with immune checkpoint inhibitors for hepatocellular carcinoma
Ann‐Lii Cheng, Chiun Hsu, Stephen L. Chan, et al.
Journal of Hepatology (2020) Vol. 72, Iss. 2, pp. 307-319
Open Access | Times Cited: 428
Biomarkers in Hepatocellular Carcinoma: Diagnosis, Prognosis and Treatment Response Assessment
Federico Piñero, Melisa Dirchwolf, Mário G. Pessôa
Cells (2020) Vol. 9, Iss. 6, pp. 1370-1370
Open Access | Times Cited: 402
Surveillance for Hepatocellular Carcinoma: Current Best Practice and Future Direction
Fasiha Kanwal, Amit G. Singal
Gastroenterology (2019) Vol. 157, Iss. 1, pp. 54-64
Open Access | Times Cited: 395
2019 Chinese clinical guidelines for the management of hepatocellular carcinoma: updates and insights
Diyang Xie, Zhenggang Ren, Jian Zhou, et al.
HepatoBiliary Surgery and Nutrition (2020) Vol. 9, Iss. 4, pp. 452-463
Open Access | Times Cited: 377
A novel lncRNA MCM3AP-AS1 promotes the growth of hepatocellular carcinoma by targeting miR-194-5p/FOXA1 axis
Yufeng Wang, Liu Yang, Tianxiang Chen, et al.
Molecular Cancer (2019) Vol. 18, Iss. 1
Open Access | Times Cited: 363
2018 Korean Liver Cancer Association–National Cancer Center Korea Practice Guidelines for the Management of Hepatocellular Carcinoma
KLCA Korean Liver Cancer Association, NCC National Cancer Center
Gut and Liver (2019) Vol. 13, Iss. 3, pp. 227-299
Open Access | Times Cited: 349
New advances in the diagnosis and management of hepatocellular carcinoma
Ju Dong Yang, Julie K. Heimbach
BMJ (2020), pp. m3544-m3544
Open Access | Times Cited: 336
Advances in the early diagnosis of hepatocellular carcinoma
Weiyi Wang, Chao Wei
Genes & Diseases (2020) Vol. 7, Iss. 3, pp. 308-319
Open Access | Times Cited: 335
Trial Design and Endpoints in Hepatocellular Carcinoma: AASLD Consensus Conference
Josep M. Llovet, Augusto Villanueva, Jorge A. Marrero, et al.
Hepatology (2020) Vol. 73, Iss. S1, pp. 158-191
Open Access | Times Cited: 321
Page 1 - Next Page

Scroll to top